News Focus
News Focus
Replies to #36768 on Biotech Values
icon url

DewDiligence

11/02/06 1:48 PM

#36776 RE: urche #36768

>So, whatever happened to ESPR?<

#msg-14028823

:-)
icon url

DownWithPumpers

11/02/06 6:53 PM

#36793 RE: urche #36768

If you search google news for ETC-216 you'll see there are several Esperion related news articles from the last month:
http://news.google.com/news?hl=en&q=etc-216&btnG=Google+Search&ie=UTF-8&oe=UTF-8&...
icon url

DewDiligence

12/01/06 2:29 PM

#38344 RE: urche #36768

What became of Esperion?

From the Q&A session of PFE’s R&D webcast yesterday:

“…a small biotech company like Esperion doesn’t necessarily have the resources to do all the things that are needed to get things ready for long-term trials… The synthesis and the analytics around the material that they had available at that time really weren’t robust enough for us to be able to start phase-3. So we’ve had to go back and do a lot of work around that. I think we’ve pretty much figured all that out and solved those problems… We hope to move into phase-2b studies in the next year.
—John LaMattina, President, Pfizer R&D